Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Market Update

Julia Lee
May 1, 2017

Market Update

Julia Lee
April 28, 2017

Market Update

Julia Lee
April 27, 2017

Market Update

Julia Lee
April 26, 2017

April Overview

Bell Direct
April 26, 2017

Market Update

Julia Lee
April 24, 2017

Market Update

Bell Direct
April 21, 2017

Market Update

Bell Direct
April 20, 2017

Market Update

Bell Direct
April 19, 2017

Market Update

Bell Direct
April 18, 2017

Market Update

Bell Direct
April 13, 2017

Market Update

Bell Direct
April 12, 2017